logo
HSBC downgrades Eli Lilly over valuation worry and strong competition

HSBC downgrades Eli Lilly over valuation worry and strong competition

CNBC28-04-2025
LLY YTD mountain Eli Lilly stock in 2025. Eli Lilly's high valuation make the stock vulnerable to a sharp decline amid broader macroeconomic concerns, according to HSBC. "We think that in the current economic environment, stocks with higher multiples are at greater risk of those multiples contracting," analyst Rajesh Kumar wrote in a Monday note. The stock currently has a forward price-to-earnings ratio of about 40 times, compared to roughly 20 times for the S & P 500. HSBC downgraded Eli Lilly stock to "reduce" from buy, and trimmed its price target to $700 per share from $1,150. HSBC's forecast calls for about 21% downside from Friday's $884.54 close. LLY YTD mountain Eli Lilly stock in 2025. The analyst also noted that the broader market might have gotten too bullish on Eli Lilly stock, especially as investors have helped hype up GLP-1 drugs and the companies that produce them. Kumas said the expectations for the the company's weight-loss drug orforglipron may be overestimated, while competition will continue to remain stiff. "One needs to bear in mind that the highest dose adverse events profile in the type-2 diabetes treatment might suggest lower compliance than injectables," Kumar said. "With c8% discontinuation rates in the type-2 diabetes trial, these trends might require a closer look in the obesity read out to confirm the market's current bullish expectations." In terms of competition, the analyst pointed to Novo Nordisk, which also produces popular GLP-1 drugs Ozempic and Wegovy. "Ozempic/Wegovy brand recognition means the market might be underestimating how much of weaker scripts trend for Ozempic/Wegovy than Mounjaro/Zepbound might stem from cannibalisation from compounders," he said. "We think when the compounders are stopped in May for Novo's brands, the script momentum gap between the two players might close." Eli Lilly stock has gained nearly 15% in 2025. Shares were off 1.6% in premarket trading Monday. Get Your Ticket to Pro LIVE Join us at the New York Stock Exchange! Uncertain markets? Gain an edge with CNBC Pro LIVE , an exclusive, inaugural event at the historic New York Stock Exchange. In today's dynamic financial landscape, access to expert insights is paramount. As a CNBC Pro subscriber, we invite you to join us for our first exclusive, in-person CNBC Pro LIVE event at the iconic NYSE on Thursday, June 12. Join interactive Pro clinics led by our Pros Carter Worth, Dan Niles and Dan Ives, with a special edition of Pro Talks with Tom Lee. You'll also get the opportunity to network with CNBC experts, talent and other Pro subscribers during an exciting cocktail hour on the legendary trading floor. Tickets are limited!
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Caitlin Clark rookie card sells for whopping $317K to continue record-breaking auction run
Caitlin Clark rookie card sells for whopping $317K to continue record-breaking auction run

New York Post

time3 hours ago

  • New York Post

Caitlin Clark rookie card sells for whopping $317K to continue record-breaking auction run

It's hard to understate Caitlin Clark's value. And one place you absolutely will not do that is at an auction. The Indiana Fever megastar, who is still out due to a groin injury, is making waves in the world of sports memorabilia, though not by her own doing. Clark's 2024 Panini Flawless Logowoman rookie card, a one-of-one edition featuring an autographed jersey patch sold for a whopping $317,000 at auction on Saturday. 3 Caitlin Clark brings the ball up court during the game against the Atlanta Dream at Gainbridge Fieldhouse on July 11, 2025 in Indianapolis, Indiana. Getty Images The auction began at a comparatively modest $50,000 on July 11, ending on Saturday at over six times the original amount. They auctioned 21 bids, according to Goldin Auctions, and quickly doubled to $100,000 at the auction just over 40 minutes after the initial bid. The bidding reached $180,000 within two days, which was the top price until a bidder came in at $200,000 on July 30. As of August 9, the highest bidder was committed to a $260,000 purchase. This was one of three Clark Logowoman cards released through Panini America's 2024 Rookie Royalty WNBA collection. 3 Caitlin Clark looks on before the game against the Seattle Storm at Climate Pledge Arena on August 03, 2025 in Seattle, Washington. Getty Images The Immaculate Logowoman sale comes after a record-breaking $660,000 auctioned off for Clark's Flawless Logowoman 1/1 at Fanatics Collect last month. That's the record holder for any women's sports card at public auction, per Yahoo. This marks the third time Clark's cards have sold for over $300,000. Clark, due to injuries, has been limited to just 13 appearances this season. 3 Caitlin Clark #22 of the Indiana Fever claps on the bench during the game against the Phoenix Mercury on August 7, 2025. NBAE via Getty Images To this point in the year, she has averaged 16.5 points, 8.8 assists and 5.5 turnovers per contest. She's only shooting 36.7 percent from the field this season, and her 3-point shooting has dropped off to 27.9 percent. The Fever, however, have found a way to pick up the pieces and be a contender in the league. They currently sit at No. 5 in the WNBA (18-14), firmly in the playoff race as they await Clark's return, though that date is unknown for the time being.

6 Ways To Keep Tariffs From Killing Your Side Gig
6 Ways To Keep Tariffs From Killing Your Side Gig

Yahoo

time10 hours ago

  • Yahoo

6 Ways To Keep Tariffs From Killing Your Side Gig

You finally found your thing, selling vintage shirts online, flipping furniture on Facebook Marketplace, or shipping hand-crafted candles from your kitchen table. But now, even that side hustle is under pressure. Tariffs are quietly raising your costs, squeezing your margins, and threatening the one thing you hoped would bring in extra income. Read More: Find Out: And if you're feeling the squeeze, you're not alone. Seventy-two percent of small and mid-sized businesses say tariffs have already increased their operating costs, and they're expected to rise even further, according to a recent 2025 HSBC survey shared with Axios. You can't control trade policy, but you can protect your margins with smart moves now. Here's how to keep tariffs from killing your side gig. Raise Prices the Smart Way Nobody wants to scare off customers. But a few well-placed increases can keep you profitable. Try smaller price bumps across several products instead of one major hike. 'Sometimes, small pricing adjustments across multiple offerings can be more digestible than one major hike,' said Karen Hastie, business coach and founder of the Chamber Perks App. Say you sell handmade soy candles. Instead of jumping your bestseller from $20 to $26, raise it to $22 and offer a bundle deal to soften the impact. Also, be upfront. A short note on your site or a social post that explains the change builds trust and keeps loyal buyers on your side. 'Communicate early and honestly with your customers. Let them know why a price change is coming and what you're doing to still deliver value,' advised Hastie. Learn More: Rethink Who You're Buying From Instead of chasing the cheapest vendor, look for someone more predictable. That might mean switching to a domestic supplier or finding a backup in a tariff-free region. 'You don't always need a cheaper supplier, just a more predictable one,' said Robert Khachatryan, CEO of Freight Right Global Logistics. 'Build redundancy into your supply chain, whether it's a second supplier in Mexico or a domestic print partner who can handle small runs during volatility.' If you're reselling sneakers or importing accessories, having a local fallback could save your whole operation if global costs spike overnight. But there's another way to reduce your exposure to tariffs entirely — by going digital. Go Digital, Even Partially The fewer physical goods you rely on, the less vulnerable you are to tariffs. Can part of your side hustle be digital? 'Digital tools aren't just for marketing, they're an alternative way to repackage your value in more scalable, cost-effective ways,' said Hastie. Think e-books, downloadable templates, memberships, or virtual consultations that deliver value without shipping or materials. Build a Mini Emergency Fund Set aside a small percentage of your earnings into a 'surprise fund.' This doesn't need to be huge, just enough to handle a sudden price increase or a delayed shipment. 'Create a mini 'surprise fund' like a personal emergency fund,' Hastie said. 'This can be built gradually by allocating a small percentage of profits each month.' If your gig involves physical products, consider stockpiling a few bestsellers ahead of expected tariff changes. Use Your E-commerce Flexibility For those who sell online, you already have an edge: agility. You can adjust prices, bundle items, or offer limited-time deals, and get real-time feedback. 'We make small changes that are just enough to preserve profit margins without scaring off customers,' said Lisa Lane, founder of Rinseroo and a Shark Tank Golden Ticket winner. When materials get expensive, test a slightly higher price or bundle slow-moving items with popular ones. Then track which combos sell. Let Pressure Push You Forward Tariffs can feel like a setback, but they can also be a signal to evolve. What starts as a supply chain issue might be the push you need to rethink how your business runs. 'Ultimately, long-term resilience comes from legal foresight and operational agility,' said William London, founding partner at Kimura London & White LLP. 'Document your supply terms, diversify risk, and view volatility not as a threat but as a signal to evolve.' That kind of mindset helps you future-proof your side gig, whether it means simplifying your inventory, changing suppliers, or building in better buffers. More From GOBankingRates 5 Ways Trump Signing the GENIUS Act Could Impact RetireesHow Far $750K Plus Social Security Goes in Retirement in Every US Region This article originally appeared on 6 Ways To Keep Tariffs From Killing Your Side Gig Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

‘Time to Double Down,' Says Top Investor About Novo Nordisk Stock
‘Time to Double Down,' Says Top Investor About Novo Nordisk Stock

Business Insider

time17 hours ago

  • Business Insider

‘Time to Double Down,' Says Top Investor About Novo Nordisk Stock

It has been a rough few seasons for Novo Nordisk (NYSE:NVO) investors, as the company's share price has tumbled some 60% over the past twelve months. Though Novo Nordisk remains the dominant player in the burgeoning GLP-1 market, worries over a complex regulatory environment, lowered guidance, and increasing competition, among other concerns, have whittled away some of its support. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. And yet, the company's Q2 2025 earnings call last reflected rising sales of 18% during the first half of the year, increased operating profits of 29% for the first six months as well, and advancements with strategic R&D initiatives including an oral weight loss medicine. The market responded with a warmth that has been missing, and NVO's share price has increased by double digits since the earnings call. Top investor James Foord thinks a turnaround is indeed beckoning. 'The recent stock correction presents a rare long-term buying opportunity, supported by a strong pipeline, manufacturing expansion, and international momentum,' asserts the 5-star investor, who is among the top 2% of TipRanks' stock pros. The investor notes that the company succeeded in delivering strong numbers in Q2, with GLP-1 drugs leading the way. While sales for Ozempic – used to treat Type 2 diabetes – jumped by 35%, the Wegovy weight loss drug saw its sales increase by 67%. And it's not just the North American market which is gaining steam, points out Foord. Japan experienced a 91% increase in GLP-1 drugs in Q2. It is this dominance in the GLP-1 market which gives Foord plenty of bullish confidence in NVO going forward – especially as Wegovy aims for a 2026 tablet form. 'Novo has shown superior performance in their latest pill version of Wegovy versus Lily, and this is very encouraging,' adds Foord. With the company spending billions of dollars to increase production capabilities, including in North Carolina, and the potential for GLP-1 drugs to be used for additional morbidities such as Alzheimer's and cardiovascular disease, the investor predicts NVO is on the road to recovery. 'With new facilities coming online, oral drugs in development, and global demand still exploding, I see NVO not only rebounding but potentially doubling in the next few years,' concludes Foord. 'I'm buying more.' No surprise here, Foord is rating NVO a Strong Buy. (To watch James Foord's track record, click here) Though slightly more tempered, Wall Street is also optimistic about NVO. With 2 Buy ratings and 3 Holds, NVO enjoys a Moderate Buy consensus rating. Its 12-month average price target of $71.75 has an upside north of 40%. (See NVO stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store